Get the Stockscreener App
2.11
3.24%
-0.05
Lantern Pharma Inc stock is traded at $2.11, with a volume of 61,267.
It is down -3.24% in the last 24 hours and up +29.01% over the past month.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.
See More
Previous Close:
$2.16
Open:
$2.12
24h Volume:
61,267
Relative Volume:
0.11
Market Cap:
$23.40M
Revenue:
-
Net Income/Loss:
$-17.12M
P/E Ratio:
-1.344
EPS:
-1.5699
Net Cash Flow:
$-15.68M
1W Performance:
+5.56%
1M Performance:
+29.01%
6M Performance:
-37.80%
1Y Performance:
-45.14%
1-Day Range:
$2.05
$2.16
1-Week Range:
$1.96
$2.33
52-Week Range:
$1.11
$5.7441
Lantern Pharma Inc Stock (LTRN) Company Profile
Name
Lantern Pharma Inc
Sector
Industry
Phone
972-277-1136
Address
1920 MCKINNEY AVENUE, DALLAS, TX
Compare LTRN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LTRN
Lantern Pharma Inc
|
2.07 | 24.42M | 0 | -17.12M | -15.68M | -1.5699 |
VRTX
Vertex Pharmaceuticals Inc
|
425.22 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
720.87 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
810.10 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
302.46 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
314.21 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-21 | Initiated | H.C. Wainwright | Buy |
Lantern Pharma Inc Stock (LTRN) Latest News
Lantern Pharma Inc. 2025 Annual Report Amendment – Executive Compensation, Corporate Governance, and Audit Committee Details - Minichart
Lantern Pharma (NASDAQ: LTRN) details pay, ownership, options - Stock Titan
Lantern Pharma Expands predictBBB Platform Into Large Quantitative Model for Drug Discovery - MEXC
Lantern Pharma (LTRN) Introduces Advanced Molecular Intelligence Platform - GuruFocus
Lantern Pharma’s predictBBB.ai Evolves Into a Real-Time Large Quantitative Model (LQM) for Precision Molecular Intelligence — Comprehensive Small Molecule Characterization & Development Analytics Available as a Web Service to Drug Developers Glob - Business Wire
Lantern receives FDA clearance for paediatric STAR-001 CNS trial - MSN
Lantern Pharma Inc (LTRN) Stock Price & 30 Year Financial Data - GuruFocus
LTRN stock gains 18% pre-market: FDA greenlights first pediatric cancer trial for AI-driven drug - MSN
Top pre-market gainers today — ELAB, ITRM, LTRN among stocks soaring before the bell - MSN
New to The Street Broadcasts Show #746 Tonight on Bloomberg Television 6:30PM EST Featuring NRx Pharma (NASDAQ:NRXP), Performance Golf, Lost Soldier Oil & Gas, Dr. Lee Gause, and CISO Global - newswire.com
CORRECTION: Join Lantern Pharma on April 30 for the First Public Demonstration of withZeta.aiA Platform to Conquer Rare Cancers - ACCESS Newswire
Join Lantern Pharma on April 30 for the First Public Demonstration of withZeta.aiA Platform to Conquer Rare Cancers - marketscreener.com
Join Lantern Pharma on April 30 for the First Public Demonstration of with Zeta.aiA Platform to Conquer Rare Cancers - Palestineherald.com
Lantern Pharma to Debut Public Demonstration of withZeta.aiA Platform to Conquer Rare Cancers on April 30 Following AACR 2026 Scientific Debut - marketscreener.com
Lantern Pharma Inc. Debuts Public Demonstration of withZeta.ai Platform - marketscreener.com
Lantern Pharma outlines $15B–$20B market potential as AI-driven pipeline advances and funding needs intensify - MSN
Lake Street Maintains Lantern Pharma(LTRN.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Lantern Pharma schedules FDA meeting on lung cancer trial changes By Investing.com - Investing.com Australia
Lantern Pharma schedules Type C meeting with FDA for Phase 2 HARMONIC trial - TipRanks
Lantern Pharma (LTRN) Plans FDA Meeting for Trial Protocol Adjus - GuruFocus
Emerging Data for Lantern Pharma’s Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure — With No Added Toxicity - BioSpace
Lantern Pharma (LTRN) Plans FDA Meeting for Trial Protocol Adjustments - GuruFocus
Lantern Pharma schedules FDA meeting on lung cancer trial changes - Investing.com
Lantern Pharma IncSchedules Type C FDA Meeting For Harmonic Protocol Amendments - TradingView
Lantern Pharma (LTRN) Stock: Technical Chart (Risk Aversion) 2026-04-18Most Discussed Stocks - Cổng thông tin điện tử tỉnh Lào Cai
Is Lantern Pharma (LTRN) stock gaining momentum (Weakens) 2026-04-18Stock Trading Network - Cổng thông tin điện tử tỉnh Tây Ninh
Funds report 834,752 Lantern Pharma (LTRN) shares in ownership update - Stock Titan
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET - ADVFN
Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational Highlights - ADVFN
Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results - ADVFN
Lantern Pharma (LTRN) Stock Revenue Growth (Trend Strengthens) 2026-04-15High Attention Stocks - Cổng thông tin điện tử tỉnh Lào Cai
Lantern Pharma (LTRN) Launches AI Platform for Cancer Research - GuruFocus
Lantern Pharma launches AI platform for rare cancer research By Investing.com - Investing.com Australia
Lantern Pharma Launches withZeta.ai — the World’s First Multi-Agentic A.I. Co-Scientist for Rare Can - PharmiWeb.com
Lantern Pharma launches AI platform for rare cancer research - Investing.com
Lantern Pharma Inc. Launches withZeta.ai, the Worlds First Multi Agentic AU Co Scientist for Rare Cancer Drug Discovery and Development - marketscreener.com
Lantern Pharma Showcases withZeta.ai Platform for Rare Cancers - TipRanks
Lantern Pharma showcases withZeta.ai platform, outlines commercial architecture and near-term revenue strategy - TradingView
Lantern Pharma (NASDAQ: LTRN) showcases withZeta.ai rare cancer AI - Stock Titan
Is Lantern Pharma (LTRN) Stock Worth Buying Now | Price at $1.61, Down 0.68%Community Chart Signals - Cổng thông tin điện tử Tỉnh Sơn La
LTRN Technical Analysis & Stock Price Forecast - Intellectia AI
Lantern Pharma (NASDAQ: LTRN) insider holds 570,000 shares, 5.1% stake - Stock Titan
Why is Lantern Pharma stock soaring Monday? - MSN
Lantern Pharma Inc (LTRN) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... By GuruFocus - Investing.com Canada
Lantern Pharma Inc (LTRN) Q4 2025 Earnings Call Highlights: Stra - GuruFocus
Lantern Pharma Inc (LTRN) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus
Lantern Pharma (LTRN) to Showcase AI Innovation in Rare Cancer R - GuruFocus
Lantern Pharma Inc Stock (LTRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lantern Pharma Inc Stock (LTRN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kreis Leslie W. | 10% Owner |
Jun 13 '25 |
Sale |
3.09 |
40,000 |
123,600 |
49,957 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 12 '25 |
Sale |
3.38 |
60,647 |
204,987 |
51,860 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 11 '25 |
Sale |
3.40 |
950 |
3,230 |
54,746 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 10 '25 |
Sale |
3.40 |
16 |
54 |
54,791 |
| Kreis Leslie W. | 10% Owner |
Jun 12 '25 |
Sale |
3.38 |
60,647 |
204,987 |
51,860 |
| Kreis Leslie W. | 10% Owner |
Jun 11 '25 |
Sale |
3.40 |
950 |
3,230 |
54,746 |
| Kreis Leslie W. | 10% Owner |
Jun 10 '25 |
Sale |
3.40 |
16 |
54 |
54,791 |
| Fletcher Aaron G.L. | 10% Owner |
May 27 '25 |
Sale |
3.05 |
21,037 |
64,163 |
56,467 |
| Fletcher Aaron G.L. | 10% Owner |
May 29 '25 |
Sale |
3.03 |
20,200 |
61,206 |
54,792 |
| Fletcher Aaron G.L. | 10% Owner |
May 28 '25 |
Sale |
2.87 |
15,000 |
43,050 |
55,753 |
0.78%
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):